Everything on Pharma

Moderna is pivoting its growth strategy toward international markets and oncology vaccines to mitigate regulatory risks and slowing respiratory vaccine growth in the US.

Impact: Diversification into cancer care and global markets reduces dependency on single-product FDA approvals and stabilizes long-term revenue.

— from AI Disruption and the Resource Super-Cycle · OHNE AKTIEN WIRD SCHWER - Tägliche Börsen-News· Feb 16, 2026